All In Biotech

Drugs by condition

Drugs approved for chronic lymphocytic leukemia

Brand-name prescription drugs and biologics whose FDA label lists chronic lymphocytic leukemia as an approved use. Matched on the label phrases: "chronic lymphocytic leukemia".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

32

Still marketed, NDA or BLA

Drug classes

8

Novel drugs

12

New molecular entities and new biologics

In development

17

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for chronic lymphocytic leukemia.

  • Gobarden (Bendamustine Hydrochloride) · Avyxa Holdings Jul 3, 2025
  • Brukinsa (Zanubrutinib) · Beone Medicines USA Accelerated approvalOrphanJun 10, 2025
  • Cyclophosphamide (Cyclophosphamide) · Sandoz Sep 12, 2023
  • Cyclophosphamide (Cyclophosphamide) · Baxter Hlthcare Corp Jun 27, 2023
  • Frindovyx (Cyclophosphamide) · Avyxa Holdings Jun 7, 2023

All approved drugs for chronic lymphocytic leukemia, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 37 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Kinase Inhibitor (8)

  • Jaypirca Pirtobrutinib · Loxo Oncol · 2023
  • Calquence Acalabrutinib · Astrazeneca · 2017
  • Zydelig Idelalisib · Gilead Sciences INC · 2014
  • Imbruvica Ibrutinib · Pharmacyclics LLC · 2013
  • Brukinsa Zanubrutinib · Beone Medicines USA · 2025
  • Imbruvica Ibrutinib · Pharmacyclics LLC · 2022
  • Calquence Acalabrutinib Maleate · Astrazeneca · 2022
  • Imbruvica Ibrutinib · Pharmacyclics LLC · 2018

CD20-directed Cytolytic Antibody (5)

  • Gazyva Obinutuzumab · Genentech · 2013
  • Rituxan Rituximab · Genentech · 1997
  • Riabni Rituximab-Arrx · Amgen INC · 2020
  • Ruxience Rituximab-Pvvr · Pfizer INC · 2019
  • Truxima Rituximab-Abbs · Celltrion INC · 2018

BCL-2 Inhibitor (1)

Thalidomide Analog (1)

  • Revlimid Lenalidomide · Bristol Myers Squibb · 2005

CD52-directed Cytolytic Antibody (1)

Alkylating Drug (1)

Endoglycosidase (1)

  • Rituxan Hycela Rituximab, Hyaluronidase (Human Recombinant) · Genentech INC · 2017

Class not listed in FDA's data (14)

Drugs in development for chronic lymphocytic leukemia

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • APG-2575lisaftoclaxPhase 310 trials

    Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • BirelentinibDZD8586Phase 37 trials

    Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)

  • NemtabrutinibMK-1026, ARQ 531Phase 36 trials

    Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma

  • RocbrutinibLP-168, NWP-775Phase 36 trials

    Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma

  • TacabrutidegBGB-16673Phase 36 trials

    BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma

  • KRT-232NavtemadlinPhase 34 trials

    Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

  • NX-5948bexobrutidegPhase 33 trials

    Nurix Therapeutics, Inc. · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials

    Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia

  • TQB3909Phase 32 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia, Myeloid Malignancy

  • Zugocabtagene geleucelCTX112Phase 23 trials

    CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy

  • EmavusertibCA-4948Phase 22 trials

    Curis, Inc. · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma

  • GNC-035Phase 22 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma

  • IDP-121Phase 22 trials

    IDP Discovery Pharma S.L. · Small Cell Lung Cancer ( SCLC ), Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

  • LacutoclaxPhase 22 trials

    Guangzhou Lupeng Pharmaceutical Company LTD. · Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)

  • ALLO-647Phase 21 trial

    Allogene Therapeutics · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

  • MS-553Phase 21 trial

    MingSight Pharmaceuticals, Inc · CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)

1 discontinued brand-name drugs whose label still names it

More on chronic lymphocytic leukemia: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.